ScholarIQanswers from OpenAlex & ORCID
Ingrid A. Mayer
ResearcherPublications, citations & collaboration network
Ingrid A. Mayer is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Ingrid A. Mayer have?
ScholarIQindexed works
Ingrid A. Mayer has 646 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Ingrid A. Mayer have?
ScholarIQcitation count
Ingrid A. Mayer has 33,342 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Ingrid A. Mayer?
ScholarIQh-index
Ingrid A. Mayer has an h-index of 74 in OpenAlex.
What is the i10-index of Ingrid A. Mayer?
ScholarIQi10-index
Ingrid A. Mayer has an i10-index of 173 in OpenAlex.
What is the ORCID of Ingrid A. Mayer?
ScholarIQorcid
The ORCID for Ingrid A. Mayer is on the source record.
What is the OpenAlex record for Ingrid A. Mayer?
ScholarIQopenalex
The OpenAlex for Ingrid A. Mayer is on the source record.
What are the most-cited papers on Ingrid A. Mayer?
ScholarIQmost cited works
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen M. Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau T. Dang, Anthony Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice A. Lyons, P. Kelly Marcom, Jennifer M. Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth O’Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy M. Sitapati, Karen L. Smith, Mary Lou Smith, Hatem Soliman, Erica Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica Young, Jennifer L. Burns, Rashmi Kumar
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff, Jennifer R. Diamond, Joyce O’Shaughnessy, Rebecca Moroose, Alessandro D. Santin, Vandana G. Abramson, Nikita Shah, Hope S. Rugo, David M. Goldenberg, Ala M. Sweidan, Robert Iannone, Sarah A. Washkowitz, Robert M. Sharkey, William A. Wegener, Kevin Kalinsky
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gϋnter von Minckwitz, Stephen Chia, Janine Mansi, Carlos H. Barrios, Michael Gnant, Z. Tomasevic, Neelima Denduluri, Robert Šeparović, Erhan Gökmen, Anna Bashford, Manuel Ruíz Borrego, Sung‐Bae Kim, Erik Jakobsen, A. Ciceniene, Kenichi Inoue, Friedrich Overkamp, Joan B. Heijns, Anne Armstrong, John S. Link, Anil A. Joy, Richard Bryce, Alvin Wong, Susan Moran, Bin Yao, Feng Xu, Alan Auerbach, Marc Buyse, Arlene Chan, Vernon Harvey, Rudolf Tomek, Nicholas J. Robert, Ira Gore, John W. Smith, Norikazu Masuda, S. Di Sean Kendall, William Graydon Harker, Katarína Petráková, Ángel Guerrero‐Zotano, Amparo Ruiz Simón, Zora Neskovic Konstantinovic, Nicholas Iannotti, Pierfrancesco Tassone, Gladys Rodriguez, Noelia Jáñez Martínez, Carmen Crespo Massieu, Snezana Smickoska, Işıl Somali, Uğur Yılmaz, Mirta Garcia Alonso, Adolfo Rosales, Soeren Cold, Ann Knoop, Debra A. Patt, Beth A. Hellerstedt, Serafin Morales Murillo, Ingrid A. Mayer, Julie A. Means‐Powell, Rina Hui, Francis M. Senecal, Richard Hendry De Boer, Zhenzhou Shen, A.A. Luczak, Joanna W.Y. Chui, Janice Tsang, István Láng, Yoshiaki Rai, Yasuo Hozumi, Albert J. ten Tije, Manish Bhandari, Cynthia R. Osborne, Shoichiro Ohtani, Kenji Higaki, Kenichi Watanabe, Kazunori TAGUCHI, Masato Takahashi, Sladjana Filipovic, Vincent Hansen, Vijayarama Phooshkooru Rao, Manish Gupta, Petar Petrov, Bruno Coudert, Željko Vojnović, Zsofia Polya, Toshiko Miyaki, Naohito Yamamoto, Stephen Brincat, Krzysztof Leśniewski-Kmak, Ewa Chmielowska, Ruemu Birhiray, Marc L. Citron, Steven W. Papish, William L. Berry, Sven Tyge Langkjer, José Á. García-Sáenz
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
Ian E. Krop, Ingrid A. Mayer, Vinod Ganju, Maura N. Dickler, Stephen Johnston, Serafín Morales, Denise A. Yardley, Bohuslav Melichar, Andres Forero‐Torres, Soo Chin Lee, Richard de Boer, Katarína Petráková, Susanne Vallentin, Edith A. Perez, Martine Piccart, Matthew J. Ellis, Eric P. Winer, Steven Gendreau, Mika K. Derynck, Mark R. Lackner, Gallia G. Levy, Jiaheng Qiu, Jing He, Peter Schmid